How Kala Pharma Could Rise 100% To 200%

Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is a recent initial public offering that could come blessed with magical upside if its possibilities blossom into a positive reality. The company is targeting the commercialization of two different Phase III product candidates. One is its KPI-121 1.0% for the treatment of inflammation and pain following ocular surgery. The other is the KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease using its proprietary mucus-penetrating particle technology.